7CC2 image
Entry Detail
PDB ID:
7CC2
Keywords:
Title:
Strategic design of catalytic lysine-targeting reversible covalent BCR-ABL Inhibitors
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2020-06-16
Release Date:
2021-06-09
Method Details:
Experimental Method:
Resolution:
2.72 Å
R-Value Free:
0.24
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 21 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Tyrosine-protein kinase ABL1
Chain IDs:A, B
Chain Length:310
Number of Molecules:2
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Strategic Design of Catalytic Lysine-Targeting Reversible Covalent BCR-ABL Inhibitors*.
Angew.Chem.Int.Ed.Engl. 60 17131 17137 (2021)
PMID: 34008286 DOI: 10.1002/anie.202105383

Abstact

Targeted covalent inhibitors have re-emerged as validated drugs to overcome acquired resistance in cancer treatment. Herein, by using a carbonyl boronic acid (CBA) warhead, we report the structure-based design of BCR-ABL inhibitors via reversible covalent targeting of the catalytic lysine with improved potency against both wild-type and mutant ABL kinases, especially ABLT315I bearing the gatekeeper residue mutation. We show the evolutionarily conserved lysine can be targeted selectively, and the selectivity depends largely on molecular recognition of the non-covalent pharmacophore in this class of inhibitors, probably due to the moderate reactivity of the warhead. We report the first co-crystal structures of covalent inhibitor-ABL kinase domain complexes, providing insights into the interaction of this warhead with the catalytic lysine. We also employed label-free mass spectrometry to evaluate off-targets of our compounds at proteome-wide level in different mammalian cells.

Legend

Protein

Chemical

Disease

Primary Citation of related structures